The Meril Blog:
Delivering Advanced Healthcare Solutions Through Research And Innovation To Improve The Quality Of Human Life
In The News
Myval associated with no device-related mortality at one year
January 03, 2020
One-year data for the Myval transcatheter aortic valve implantation (TAVI) system indicate it is associated with 100% freedom from device related mortality at one year.
In The News
MeRes100 BRS - the World's First Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold - Shows Consistent Long-term Positive Safety With Consistent Low MACE rates and Zero Scaffold Stent
January 03, 2020
Meril's recently CE-approved MeRes100, used for the treatment of de-novo coronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rate of 1.87% at three years as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years.
In The News
TCT 2019: Low rate of MACE at 12 months with “world’s thinnest stent”
December 28, 2019
K Sivaprasad (Govt TD Medical College, Alappuzha, India) reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA) yesterday that the Evermine 50 stent (Meril Life), which has a strut thickness of 50μm, is associated with a low rate of major adverse events (MACE) at 12 months.
ABOUT
Founded in 2006, Meril is an India-based global medical device company that is dedicated to the innovation, design and development of novel, clinically relevant and state-of-the-art devices
LEARN MORE
